Physician profile
Michael Perini
NPI 1841238045
$2,018.08
in general payments reported to CMS, 2019-2025
28 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.79 · 2023: $14.78 · 2024: $876 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.74 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.08 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $184.79 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $168.33 | 2024-2025 | |
| Lilly USA, LLC | $106.93 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Vanda Pharmaceuticals INC. | $104.08 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.02 | 2024-2025 | Caplyta |
| Amgen INC. | $60.95 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $55.51 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $47.60 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $39.02 | 2025 | Trintellix |
| Dexcom, INC. | $37.92 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $37.81 | 2024 | |
| Lundbeck LLC | $37.65 | 2025 | Rexulti |
| Viatris Specialty LLC | $37.33 | 2025 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $31.46 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $30.95 | 2023-2024 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.84 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $29.82 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $25.24 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $24.64 | 2024 | Inspire |
| Vifor Pharma, INC. | $22.79 | 2019 | |
| Alkermes, INC. | $21.39 | 2024 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $20.95 | 2025 | Ajovy |
| Bioventus LLC | $19.60 | 2024 | Supartz Fx Sodium Hyaluronate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.34 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $14.81 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $13.49 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Perini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.